Orbital Therapeutics vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Orbital Therapeutics is a next-gen RNA biotech that raised $270M Series A in 2023; advancing circular RNA and in vivo CAR-T programs for autoimmune disease; Bristol Myers Squibb announced a $1.5B acquisition in 2025;
About
Orbital Therapeutics is a clinical-stage biotechnology company founded in 2022 and headquartered in Cambridge, Massachusetts, with a mission to unlock the full potential of RNA medicines. The company operates at the frontier of RNA biology, advancing a platform that spans circular RNA, self-amplifying RNA, and in vivo CAR-T cell therapies — technologies designed to go beyond the mRNA approaches pioneered during the COVID-19 era. Orbital was co-founded by leading RNA scientists and backed by ARCH Venture Partners, a16z Bio + Health, Newpath Partners, the Abu Dhabi Growth Fund, and Redmile Group, among others.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Orbital Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.